Critical Survey: Silo Pharma (NASDAQ:SILO) vs. Arcutis Biotherapeutics (NASDAQ:ARQT)

Silo Pharma (NASDAQ:SILO – Get Free Report) and Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Volatility & Risk

Silo Pharma has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Silo Pharma and Arcutis Biotherapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silo Pharma 1 0 0 0 1.00
Arcutis Biotherapeutics 0 2 8 0 2.80

Arcutis Biotherapeutics has a consensus target price of $39.75, indicating a potential upside of 46.41%. Given Arcutis Biotherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Silo Pharma.

Earnings & Valuation

This table compares Silo Pharma and Arcutis Biotherapeutics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Silo Pharma $70,000.00 35.77 -$4.23 million ($2.77) -0.57
Arcutis Biotherapeutics $376.07 million 9.13 -$16.14 million $0.21 129.29

Silo Pharma has higher earnings, but lower revenue than Arcutis Biotherapeutics. Silo Pharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Silo Pharma and Arcutis Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Silo Pharma -6,726.39% -81.75% -66.35%
Arcutis Biotherapeutics 5.88% 14.18% 6.28%

Institutional & Insider Ownership

5.6% of Silo Pharma shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Arcutis Biotherapeutics beats Silo Pharma on 10 of the 13 factors compared between the two stocks.

About Silo Pharma

(Get Free Report)

Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on treatments for central nervous system disorders and pain conditions. Its research programs include potential therapies for post-traumatic stress disorder, Alzheimer’s disease and chronic pain. The company works on drug candidates and delivery approaches involving compounds such as ketamine, including formulations intended to support targeted or sustained treatment. Silo’s programs remain in development, and the company does not have a marketed product.

About Arcutis Biotherapeutics

(Get Free Report)

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.

Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.